Adult ECAT protocol

Shortness of breath with a history of asthma

A2.2 Published: December 2023. Printed on 22 Nov 2024.

QR code link to ECI website

Get the latest version


Any person, 16 years of age and over, presenting with a history of asthma.

This protocol is intended to be used by registered and enrolled nurses within their scope of practice and as outlined in The Use of Emergency Care Assessment and Treatment Protocols (PD2024_011). Sections marked triangle or diamond indicate the need for additional prerequisite education prior to use. Check the medication table for dose adjustments and links to relevant reference texts.

If the patient has:

Follow patient's own management plan, if available.

History prompts, signs and symptoms

These are not exhaustive lists. Maintain an open mind and be aware of cognitive bias.

History prompts

  • Presenting complaint
  • Onset of symptoms
  • Triggers, including thunderstorm asthma or breathlessness on exertion
  • Recent illness
  • Pain assessment – PQRST
  • Pre-hospital treatment, including steroid use
  • Past admissions
  • Medical and surgical history, including ICU or intubations
  • Current medications
  • Known allergies
  • Recent contact with sick persons
  • Smoking history

Signs and symptoms

  • Respiratory distress
  • Tachypnoeic
  • Tachycardia
  • Limitations in talking ability
  • Cough
  • With or without wheeze
  • Palpitations
  • Fatigue
  • Anxiety

Red flags

Recognise: identify indicators of actual or potential clinical severity and risk of deterioration.

Respond: carefully consider alternative ECAT protocol. Escalate as per clinical reasoning and local CERS protocol, and continue treatment.

Historical

  • Current or recent steroid therapy
  • Recurrent admission for asthma
  • Pregnant or postpartum (3/12)
  • Previous history of intubation or ICU admission
  • Recent long-haul travel
  • Unresponsive to pre-hospital management

Clinical

  • Altered level of consciousness
  • Tripod positioning
  • Hypoxia
  • Severe respiratory distress
  • Talking in words only
  • Bradypnoea
  • Silent chest
  • Cyanosis
  • Chest pain
  • Exhaustion
  • Pre-syncope

Remember adult at risk: patient or carer concern, frailty, multiple comorbidities or unplanned return.

Clinical assessment and specified intervention (A to G)

If the patient has any Yellow or Red Zone observations or additional criteria (as per the relevant NSW Standard Emergency Observation Chart), refer and escalate as per local CERS protocol and continue treatment.

Position

AssessmentIntervention

General appearance/first impressions

Position of comfort

Preferably semi-reclined or upright

Airway

AssessmentIntervention

Patency of airway

Maintain airway patency

Consider airway opening manoeuvres and positioning

Breathing

AssessmentIntervention

Life-threatening or critical asthma

  • SpO2 less than 90% or clinical cyanosis
  • Bradypnoea indicates respiratory exhaustion
  • Severe respiratory distress or poor respiratory effort
  • Soft or absent breath sounds
  • Unable to speak

Assist ventilation, if clinically indicated

Apply oxygen

If peri-arrest, give adrenaline 0.5 mg of 1:1000 IM once only

Auscultate chest

Give with 8–10 L of oxygen via nebuliser:

  • place 2 x 5 mg salbutamol nebules into nebuliser chamber and give via continuous nebulisation – repeat as required
  • and nebulised ipratropium 500 microg (added to salbutamol), every 20 minutes, for 3 doses

and give hydrocortisone 100 mg IV/intraosseous, once only

Prepare for potential non-invasive ventilation or intubation

If anaphylaxis is suspected, switch to anaphylaxis or allergic reactions protocol.

Severe asthma

  • SpO2 90–94%
  • Respiratory rate over 25 breaths per minute
  • Paradoxical chest wall movement, chest sucks in when patient breathes in
  • Use of accessory muscle of neck or intercostal muscles or “tracheal tug” during inspiration or subcostal recession, abdominal breathing
  • Can only speak a few words in one breath

Assist ventilation, if clinically indicated

If SpO2 is less than 92%, apply oxygen

Select:

Able to breathe via spacer

Give:

  • 12 puffs salbutamol 100 microg/puff MDI via spacer, every 20 minutes, for 3 doses
  • and 8 puffs ipratropium 21 microg/puff MDI via spacer, every 20 minutes, for 3 doses
  • and give:
    • prednisolone 50 mg orally once only
    • or if unable to tolerate oral prednisolone, hydrocortisone 100 mg IV/intraosseous, once only

Unable to breathe adequately via spacer

Give:

  • with 8–10 L oxygen via nebuliser: nebulised salbutamol 5 mg and ipratropium 500 microg every 20 minutes for 3 doses
  • and give:
    • prednisolone 50 mg orally once only
    • or if unable to tolerate oral prednisolone, hydrocortisone 100 mg IV/intraosseous, once only

Mild or moderate asthma

  • SpO2 over 94%
  • Respiratory rate less than 25 breaths per minute
  • Respiratory distress is not severe
  • Wheeze or normal breath sounds
  • Can finish a sentence in one breath

Give:

  • 12 puffs salbutamol 100 microg/puff MDI via a spacer. Repeat once after 20 minutes, if required
  • and prednisolone 50 mg orally, once only

If there is an inadequate response to the treatment, manage as per the next severity box

Circulation

AssessmentIntervention

Perfusion (capillary refill, skin warmth and colour)

Pulse

Blood pressure

Cardiac rhythm

Assess circulation

Attach cardiac monitor and complete 12 lead ECG if BP/HR are within the Yellow or Red Zones , or where clinically relevant, e.g. irregular pulse, palpitations, syncope, shock, respiratory compromise, cardiac history or clinical concern

IVC and/or pathology

Insert IV cannula, if trained

If unable to obtain IV access, consider intraosseous, if trained

See pathology section

Signs of shock:

tachycardia and CRT 3 seconds and over

and/or abnormal skin perfusion

and/or hypotension

If signs of shock present and/or SBP less than 90 mmHg, give 250 mL of sodium chloride 0.9% IV/intraosseous bolus

Repeat every 10 minutes (up to 1000 mL) until SBP over 90 mmHg or signs of shock have resolved

Disability

AssessmentIntervention
ACVPU

If ACVPU shows reduced level of consciousness, continue to GCS, pupillary response and limb strength

GCS, pupillary response and limb strength

Obtain baseline and repeat assessment as clinically indicated

Pain

Assess pain. If indicated, give early analgesia as per analgesia section then resume A to G assessment

Exposure

AssessmentIntervention
Temperature

Measure temperature

Skin inspection, including posterior surfaces

Check and document any abnormalities

Fluids

AssessmentIntervention
Hydration status – last ate, drank, bowels opened, passed urine or vomited Commence fluid balance chart, as required
Nausea and/or vomiting If present, see nausea and/or vomiting section
NBM

Consider clear fluids or NBM based on red flags and clinical severity

Glucose

AssessmentIntervention

BGL

Measure BGL, if clinically indicated

If less than 4 mmol/L, consider hypoglycaemia protocol

Repeat and document assessment and observations to monitor responses to interventions, identify developing trends and clinical deterioration. Escalate care as required according to the local CERS protocol.

Focused assessment

Complete a respiratory focused assessment.

Precautions and notes

Delivery of short-acting beta-agonists via MDI and spacer is equally effective as nebulisation, provided the patient can inhale effectively.

Interventions and diagnostics

Specific treatment

If ineffective respiratory effort, consider non-invasive ventilation (NIV) where available and escalate as per local CERS protocol if required.


Analgesia

If pain score 1–6 (mild to moderate): give paracetamol 1000 mg orally once only.

If severe pain present, give analgesia and escalate as per local CERS.

If chest pain present, consider chest pain protocol.


Nausea and/or vomiting

If nausea and/or vomiting is present, give:

  • metoclopramide 10 mg orally or IV/IM once only (over 20 years only)
  • or ondansetron 4 mg orally or IV/IM. If symptoms persist after 60 minutes, repeat once, maximum dose 8 mg
  • or prochlorperazine 5 mg orally once only or 12.5 mg IV/IM once only

Choice of antiemetic should be determined by cause of symptoms.


Radiology

  • If life threatening or concern for pneumothorax: CXR

Pathology

  • If severe or life-threatening: FBC, UEC, VBG
  • Temp less than 35°C, or 38.5°C and over: take two sets of blood cultures from two separate sites

Medications

The shaded sections in this protocol are only to be used by registered nurses who have completed the required education.

Drag the table right to view more columns or turn your phone to landscape

Drug Dose Route Frequency

0.5 mg
(0.5 mL of 1:1000)

IM

Peri arrest: once only

100 mg

IV/intraosseous

Once only

Ipratropium

500 microg nebule

Inhalation via nebuliser

Critical/life-threatening or severe asthma and cannot use spacer

Repeat every 20 minutes to a total of 3 doses

OR

8 puffs
(21 microg/puff MDI)

Inhalation via spacer

Severe asthma

Repeat every 20 minutes to a total of 3 doses

Metoclopramide R

Over 20 years:
10 mg

Oral/IV/IM

Once only

Ondansetron

4 mg

Maximum dose 8 mg

Oral/IV/IM

Repeat once if required after 60 minutes

Oxygen

2–15 L/min, device dependent

Inhalation

Continuous

Paracetamol H

1000 mg

Oral

Pain score 1–10

Once only

50 mg

Oral

Do not give if patient has been given hydrocortisone

Once only

5 mg

Oral

Once only

OR

12.5 mg

IV/IM

Once only

10 mg (use two 5 mg nebules)

Inhalation via nebuliser

Life-threatening asthma
Continuous nebulisation until dyspnoea improves

OR
5 mg nebule

Inhalation via nebuliser

Severe asthma if cannot breathe through a spacer
Repeat every 20 minutes to a total of 3 doses

OR

12 puffs
(100 microg/puff MDI)

Inhalation via spacer

Severe asthma
Repeat every 20 minutes to a total of 3 doses

OR

12 puffs
(100 microg/puff MDI)

Inhalation via spacer

Mild to moderate asthma
Repeat once if required after 20 minutes

Sodium chloride 0.9%

250 mL

Maximum dose 1000 mL

IV/intraosseous

Bolus

Repeat every 10 minutes (up to 1000 mL) until SBP over 90 mmHg or signs of shock have resolved

Medications with contraindications or requiring dose adjustment are marked:

  • H for patients with known hepatic impairment
  • R for patients with known renal impairment.

Escalate to medical or nurse practitioner.

References

Hide references

Evidence informed

Information was drawn from evidence-based guidelines and a review of latest available research. For more information, see the development process.

Collaboration

This protocol was developed by the ECAT Working Group, led by the Agency for Clinical Innovation. The group involved expert medical, nursing and allied health representatives from local health districts across NSW. Consensus was reached on all recommendations included within this protocol.

Currency Due for review: Jan 2026. Based on a regular review cycle.
Feedback Email ACI-ECIs@health.nsw.gov.au

Accessed from the Emergency Care Institute website at https://aci.health.nsw.gov.au/ecat/adult/shortness-of-breath-asthma

Back to top